Inkbit

Organovo Initiates Contracting For Their 3D Bioprinted Human Liver Cells

ST Dentistry

Share this Article

One of the more exciting companies within the 3D Printing space is Organovo. The San Diego based company is using 3D printing technology to print live human tissue. It sounds like something out of a science fiction organovo-1novel, but the company has been making tremendous progress over the last couple of years. Organovo’s ultimate goal is to be able to print out entire functioning human organs. Although such an accomplishment is still many years away, they are already turning heads, and garnering interest from major pharmaceutical companies that are looking to use their bioprinted tissue for pre-clinical trials .

Every year billions of dollars are spent performing pre-clinical testing for drug discovery. These tests usually rely on a variety of methods, most of which are not all that accurate. What Organovo has been working diligently on, has been the development of human tissue samples, specifically liver tissue, aimed towards pre-clinical drug testing and discovery. This week the company announced that they have begun initiating contracts for their patented 3D printed human liver tissue samples, with various pharmaceutical and biotech firms.

Organovo’s Chairman and Chief Executive Officer, Keith Murphy, stated “Organovo has received interest in advance of our planned launch from top 15 pharma company customers, small to midsize pharma companies, biotechnology companies, and private venture capital backed pharmaceutical development firms. The compelling data already generated on the organovo-featperformance of the 3D Human Liver Tissue has driven this interest, we believe, and I’m pleased that our team was able in a short time to accomplish all of the hard work that allowed us to begin signing contracts. We’ll be able to deliver results for proprietary compounds and other needs, while completing the work for fuller product and service launch on our original timeline.”

The company expects to expand their offerings to more clients as the year progresses. The human liver tissue that they are able to print, is capable of surviving long term studies, making them ideal for testing the long term affects of a drug on the human liver. This is a major step towards further monetization of their technology, and will likely allow them to push forward with additional bioprinting applications that they have shown interest in. Discuss this article at the Organovo forum thread at 3DPB.com.

organovo-2

3D Printed Human Liver Tissue

Share this Article


Recent News

3D Printing News Briefs, June 3, 2023: Beta Software, 3D Printing Walls, & More

3D Systems Confirms Bid to Buy Stratasys to Create $1.84B 3D Printing Company



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

3D Printing News Unpeeled: Stratasys, Nano Dimension and 3D Systems

Today we’re talking about all the merger options on offer between Desktop Metal, Stratasys, Nano Dimension and 3D Systems. It seems like most people in this industry are publicly saying...

3D Printing Financials: Stratasys Reveals Strong Q1 Earnings Ahead of $1.8B Merger with Desktop Metal

Following Nano Dimension (Nasdaq: NNDM)’s numerous failed attempts to acquire Stratasys (Nasdaq: SSYS), the 3D printing pioneer finally announced its merger with Desktop Metal (NYSE: DM) in a staggering deal...

XJet Sets Sights on Metal 3D Printing IPO

XJet, a 3D printing manufacturer based in Rehovot, Israel, plans to raise up to $10 million through an initial public offering (IPO) on the Nasdaq. According to a registration statement...

Featured

Printing Money Emergency Broadcast: Stratasys and Desktop Metal to Merge in All-stock Deal

In what is shaping up to be the biggest deal in the 3D printing industry of 2023, Stratasys and Desktop Metal will combine to form a $1.8 billion company. Alex...